Skip to main content
SpringerLink
Log in

Autosomal-dominante polyzystische Nierenerkrankung

Autosomal dominant polycystic kidney disease

  • Leitthema
  • Published:
Der Nephrologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287–1301

    Article  PubMed  Google Scholar 

  2. Harris PC, Torres VE (2014) Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease. J Clin Invest 124:2315–2324

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Torres VE, Harris PC (2014) Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol 25:18–32

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Grantham JJ, Torres VE, Chapman AB et al (2006) Volume progression in polycystic kidney disease. N Engl J Med 354:2122–2130

    Article  CAS  PubMed  Google Scholar 

  5. Kistler AD, Poster D, Krauer F et al (2009) Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 75:235–241

    Article  PubMed  Google Scholar 

  6. Chen D, Ma Y, Wang X et al (2014) Clinical characteristics and disease predictors of a large Chinese cohort of patients with autosomal dominant polycystic kidney disease. PLoS One 9:e92232

    Article  PubMed Central  PubMed  Google Scholar 

  7. Cornec-Le Gall E, Audrezet MP, Chen JM et al (2013) Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol 24:1006–1013

    Article  Google Scholar 

  8. Chapman AB, Johnson AM, Gabow PA, Schrier RW (1994) Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:1349–1354

    CAS  PubMed  Google Scholar 

  9. Schrier RW, Brosnahan G, Cadnapaphornchai MA et al (2014) Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol 25:2399–2418

    Article  CAS  PubMed  Google Scholar 

  10. Wüthrich RP, Mei C (2014) Pharmacological management of polycystic kidney disease. Expert Opin Pharmacother 15:1085–1095

    Article  PubMed  Google Scholar 

  11. Serra AL, Poster D, Kistler AD et al (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363:820–829

    Article  CAS  PubMed  Google Scholar 

  12. Perico N, Antiga L, Caroli A et al (2010) Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 21:1031–1040

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Walz G, Budde K, Mannaa M et al (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363:830–840

    Article  CAS  PubMed  Google Scholar 

  14. Hogan MC, Masyuk TV, Page LJ et al (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21:1052–1061

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Ruggenenti P, Remuzzi A, Ondei P et al (2005) Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68:206–216

    Article  CAS  PubMed  Google Scholar 

  16. Caroli A, Perico N, Perna A et al (2013) Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet 382:1485–1495

    Article  CAS  PubMed  Google Scholar 

  17. Torres VE, Chapman AB, Devuyst O et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407–2418

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Wüthrich RP, Mei C (2012) Aquaretic treatment in polycystic kidney disease. N Engl J Med 367:2440–2442

    Article  PubMed  Google Scholar 

  19. Torres VE, Abebe KZ, Chapman AB et al (2014) Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 371:2267–2276

    Article  PubMed Central  PubMed  Google Scholar 

  20. Schrier RW, Abebe KZ, Perrone RD et al (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255–2266

    Article  PubMed Central  PubMed  Google Scholar 

  21. Bae KT, Grantham JJ (2010) Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 6:96–106

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. R.P. Wüthrich gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Klinik für Nephrologie, Universitätsspital Zürich, Rämistr. 100, CH-8091, Zürich, Schweiz

    R.P. Wüthrich

Authors
  1. R.P. Wüthrich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R.P. Wüthrich.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wüthrich, R. Autosomal-dominante polyzystische Nierenerkrankung. Nephrologe 10, 376–378 (2015). https://doi.org/10.1007/s11560-015-0998-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-015-0998-x

Search

Navigation